EWA
GALT icon

EverSource Wealth Advisors’s Galectin Therapeutics GALT Stock Holding History

EverSource Wealth Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$4 – 4440
2025
Q4 		$4 Sell
1
-76
-99% -$400 ﹤0.01% 4256
2025
Q3 		$326 Sell
77
-84
-52% -$316 ﹤0.01% 4038
2025
Q2 		$340 Buy
161
+141
+705% +$211 ﹤0.01% 3981
2025
Q1 		$24 Sell
20
-26
-57% -$36 ﹤0.01% 3959
2024
Q4 		$59 Buy
+46
New +$110 ﹤0.01% 3620

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

EverSource Wealth Advisors's GALT Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 1 share — an estimated $4 sold.

EverSource Wealth Advisors first reported a position in GALT in Q4 2024 and held it in 5 quarters. The position peaked at $340 in Q2 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • EverSource Wealth Advisors reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EverSource Wealth Advisors sold 1 Galectin Therapeutics share in Q1 2026, an estimated $4.
  • EverSource Wealth Advisors first reported a position in Galectin Therapeutics in Q4 2024 and held it in 5 quarters.
  • EverSource Wealth Advisors's Galectin Therapeutics position peaked at $340 in Q2 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.